| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Commercial Officer
2 companies
Nicole Sweeny is Chief Commercial Officer at KALV, with reported holdings spanning 2 companies. Nicole Sweeny's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $12.2M at current prices.
Our model assigns Nicole Sweeny a below-average insider score of 37/100, based on 3 past trades. On a 3-month view, 33.3% of the rated trades came out ahead, averaging -5.5% over three months.
Nicole Sweeny's largest disclosed position is in PRAX as Chief Commercial Officer, worth about $10.8M.
Nicole Sweeny has 14 Form 4 filings on record from February 2021 to June 2026, across 3 companies: Director at Monopar Therapeutics (MNPR), 2026; Chief Commercial Officer at KalVista Pharmaceuticals (KALV), 2025–2026; Chief Commercial Officer at Praxis Precision Medicines (PRAX), 2021–2023.
The 21 reported transactions were 6 option or other derivative awards, 5 option exercises, 4 open-market sales and 3 tax withholdings, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 4 sales worth about $133K.
The largest open-market sale was 3,813 shares of KALV at an average $13.45 on November 24, 2025, about $51K.
None of the 4 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 17, 2026 | KALV Kalvista Pharmaceuticals, Inc. | Chief Commercial Officer | Sale+OE | 1,862 | $20.22 | $37,642.75 | -3.5% | - | - | |
| Nov 24, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Commercial Officer | Sale+OE | 3,813 | $13.45 | $51,288.66 | -8.8% | +16.5% | - | |
| Aug 25, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Commercial Officer | Sale+OE | 1,480 | $13.42 | $19,861.60 | -4.4% | +2.8% | - | |
| Aug 22, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Commercial Officer | Sale+OE | 1,864 | $13.22 | $24,647.30 | -6.1% | -2.9% | - |